Risk and protective factors for thrombosis in systemic lupus erythematosus: Results from a large, multi-ethnic cohort

Annals of the Rheumatic Diseases

Volumn 68, Issue 2, 2009, Pages 238-241

  Kaiser, R ^a   Cleveland, C M ^a   Criswell, L A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Division of Rheumatology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYCHLOROQUINE; PHOSPHOLIPID ANTIBODY;

ADULT; AGED; ARTICLE; CHILD; DISEASE DURATION; ETHNICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHRITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; QUESTIONNAIRE; SCHOOL CHILD; SMOKING; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CALIFORNIA; CHILD; FEMALE; HUMANS; HYDROXYCHLOROQUINE; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MIDDLE AGED; RISK FACTORS; SEX FACTORS; SMOKING; THROMBOSIS; YOUNG ADULT;

EID: 58849159669     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.093013     Document Type: Article

References (18)

1. Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol 2001;13:345-51.
2. Mok CC, Tang SS, To CH, Petri M. Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. Arthritis Rheum 2005;52:2774-82.
3. Feinbloom D, Bauer KA. Assessment of hemostatic risk factors in predicting arterial thrombotic events. Arterioscler Thromb Vase Biol 2005;25:2043-53.
4. Toloza SM, Uribe AG, McGwin G Jr, Alarcon GS, Fessler BJ, Bastian HM, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004;50:3947-57.
5. White RH, Zhou H, Murin S, Harvey D. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost 2005;93:298-305.
6. Jordan JM, Lawrence R, Kington R, Fraser P, Karlson E, Lorig K, ef al. Ethnic health disparities in arthritis and musculoskeletal diseases: report of a scientific conference. Arthritis Rheum 2002;46:2280- 6.
7. Thorburn CM, Prokunina-Olsson L, Sterba KA, Lum RF, Seldin MF, Alarcon-Riquelme ME, et al. Association of PDCD1 genetic variation with risk and clinical manifestations of systemic lupus erythematosus in a multiethnic cohort. Genes immun 2007;8:279-87.
8. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
9. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Fiothfield NF, et al. The 1982 revised criteria tor the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
10. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127(8 Pt 2):757-63.
11. Fessler BJ, Alarcon GS, McGwin G Jr, Roseman J, Bastian HM, Friedman AW, et al. Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 2005;52:1473-80.
12. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990;112:682-98.
13. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA Jr, Jansen-McWilliams I, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997;145:408-15.
14. Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology (Oxford) 2002;41:924-9.
15. Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 1996;5(Suppl 1):S16-22.
16. Siso A, Ramos-Casals M, Bove A, Brito-Zeron P, Soria N, Munoz S, et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. Lupus 2008;17:281- 8.
17. Wallace DJ, Linker-Israeli M, Metzger AL, Stecher VJ. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. Lupus 1993;2(Suppl 1):S13-15.
18. Ho KT, Ahn CW, Alarcon GS, Baethge BA, Tan FK, Roseman J, et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology (Oxford) 2005;44:1303-7.